background_1 background_2

Emplois / Jobs

Three-Year Funded Post-Doctoral Position on Dendritic Cells and Macrophages Immunobiology

The team ‘Genetic dissection of the function of T cells and dendritic cells’
at Centre d’Immunologie de Marseille-Luminy (CIML) wishes to recruit a
highly motivated Associate Research Fellow to further dissect the role
of dendritic cell and macrophages in tumor immunobiology. This position
is available for 36 months, and needs to start between November 2017
and June 2018. The successful candidate will work in the context of a
project lead by Bernard Malissen and Sandrine Henri. The project aims
at deciphering the immunobiology of macrophages using two
innovative mouse models allowing conditional gene depletion in vivo
and at boosting cutaneous immunity using DC targeting and potent
adjuvants. We are looking for a candidate with a strong expertise in
immunology, flow cytometry and cellular biology. Experience in animal
studies is preferred but not necessary. The successful candidate will work
in a group of 16 persons (http://www.ciml.univ-mrs.fr/science/lab-bernardmarie-
malissen/home) and benefit from the supportive CIML scientific
environment

Requirements
The candidate must hold a Ph.D. in Immunology. Applicants should submit
to bernardm (at) ciml.univ-mrs.fr and henri (at) ciml.univ-mrs.fr a curriculum
vitae, a brief description of their research accomplishments and career
goals, the list of their publications and the name of three referees.

Contact:
bernardm (at) ciml.univ-mrs.fr and henri (at) ciml.univ-mrs.fr






POST-DOCTORAL POSITION AT INSTITUT CURIE (PARIS)

Context and environment: A post-doc position is available with Elodie Segura in the
“Immunity and Cancer” department of Institut Curie. The group studies the biology of human
antigen-presenting cells in health and pathology, by combining analysis of human cells
directly isolated from tissues, in vitro models using human cells, and in vivo models in mice.

During inflammation, monocytes are rapidly recruited and differentiate in situ into monocytederived
macrophages (mo-Mac) and monocyte-derived dendritic cells (mo-DC). In chronic
inflammatory diseases, mo-DC fuel the inflammation and are major contributors to tissue
damage, while in cancer mo-Mac play a key role in suppressing anti-tumoral immune
responses. How monocytes differentiate into mo-DC or mo-Mac is still poorly characterized.
A better understanding of the molecular ontogeny of monocyte-derived cells would provide
novel targets for the therapeutic manipulation of monocyte differentiation. We have recently
shown that the Aryl Hydrocarbon Receptor is a molecular switch for directing monocyte
differentiation towards mo-DC versus mo-Mac (Goudot et al, 2017). The successful
candidate will employ molecular biology, cellular immunology and mouse models to unravel
the transcriptional networks involved in the regulation of mo-Mac versus mo-DC
differentiation by the Aryl Hydrocarbon Receptor.

Institut Curie is one of the largest European institutions for cancer research with a strong
interdisciplinary tradition and state-of-the-art core facilities. It is located in the center of Paris
(France), in a rich cultural and scientific environment. The Immunology department, headed
by Sebastian Amigorena, includes 10 independent research groups in fundamental and
translational immunology, working in a very collaborative and international environment.

Candidate profile: We are looking for a qualified, intellectually curious and highly motivated
candidate holding a Ph.D. in biology, preferably in immunology, molecular biology or
genomics. Familiarity with the following techniques will be an advantage but is not
mandatory: flow cytometry, gene regulation/chromatin biology, lentiviral infections and bioinformatics.
Strong organizational and communication skills and independence are essential.
Written and spoken English is mandatory. Salary will be dependent on diploma and
experience.

Application : Opened from September 2017 until filled.
Please send CV, motivation letter and contact details of at least two persons able to provide
references to elodie.segura (at) curie.fr

http://esegura-lab.org
http://u932.curie.fr/

Goudot C, Coillard A, Villani AC, Gueguen P, Cros A, Sarkizova S, Tang-Huau TL, Bohec M,
Baulande S, Hacohen N, Amigorena S, Segura E (2017). Aryl hydrocarbon receptor controls
monocyte differentiation into dendritic cells versus macrophages., Immunity. 47: 1-15.





Postdoctoral position available in France in the teams of Marc DALOD, at Centre
d’Immunologie de Marseille-Luminy, Marseille, & Nicolas Manel, at Institut Curie, Paris.

Deadline for application: September 15th 2017.
Starting date: February 1st 2018
Title of the research program: Deciphering the molecular regulation of the differential
interaction of human dendritic cells with HIV.
Scientific background for the project:
Vertebrate resistance to viruses relies on both innate and adaptive immunity. Dendritic cells (DC)
play a crucial role in this process. They are able to sense infections to initiate innate immune
responses, and then to orchestrate the transition towards the activation of adaptive immunity. DC
constitute a heterogeneous cell population, defined by distinct cell types endowed with different
functions. DC are pivotal targets of HIV due to their critical ability to regulate the immune response.
Knowledge on the functional specialization of DC types and its molecular regulation is still largely
incomplete, especially in the context of HIV infection. We have recently discovered that distinct DC
types are functionally specialized for HIV infection. In particular, we have uncovered that DC1
(CD141+XCR1+) are constitutively resistant to infection by HIV and several other enveloped viruses.
This creates a 'division of antiviral labor' across DC and results in a cooperation between DC types
to activate adaptive immunity. The goal of the project is to discover the molecular mechanisms that
enable the division of labor and the DC cooperation for antiviral immune responses.
Specific objectives of the research program:
The applicant will use in vitro models of human DC types to decipher the role of candidate genes in
the control of the differential antiviral resistance across DC subsets. In addition, the applicant will
develop new cellular in vitro models of DC to overcome current limitations in the experimental study
of DC types.
Environment: The teams belong to an Excellency Laboratory (DC-BIOL Labex) headed by Sébastian
Amigorena (Curie) and Bernard Malissen (Marseille). The applicant will benefit from strong
collaborations within the Labex DC-BIOL and with several Institutes abroad. The project will be
performed in close collaboration between the laboratories of Marc Dalod (CIML) and Nicolas Manel
(Institut Curie). The applicant will be hosted at the most appropriate location, based on previous
experience of the candidate and personal constraints.
The applicant will benefit from highly collaborative environments and state-of-the-art technological
platforms. Institut Curie is located in the center of Paris in a culturally and scientifically rich
environment. CIML is located on the Luminy campus regrouping fundamental research laboratories
in all disciplines of life sciences, in informatics, physics, chemistry and mathematics, and biotech
start-up companies, including several that emerged from CIML work: Immunotech, Innate Pharma,
Oz Bioscience and HalioDx.
Applicant profile: The applicant must have a Ph.D. in Virology and a documented positive experience
in studying retroviruses or using lentivectors, or a Ph.D. in Immunology and a document positive
experience in studying human immune cells in vitro. Excellent communication skills and team spirit
are essential.
Contact: Please send applications by e-mail to dalod@ciml.univ-mrs.fr and nicolas.manel@curie.fr,
including i) a curriculum vitae with a brief summary of professional experience, education, key
qualifications, awards, and the name of 2 referees with their contact information, ii) a complete list
of publications, and iii) a motivation letter.
References:
Silvin et al., Science Immunology 2017. doi: 10.1126/sciimmunol.aai8071 .
Gentili et al., Science 2015. doi: 10.1126/science.aab3628 .
Balan et al., J Immunol 2014. doi: 10.4049/jimmunol.1401243 .